Comprehensive Financial Consultants Institutional Inc. Purchases 824 Shares of Edwards Lifesciences Co. (NYSE:EW)

Comprehensive Financial Consultants Institutional Inc. boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,657 shares of the medical research company’s stock after purchasing an additional 824 shares during the period. Comprehensive Financial Consultants Institutional Inc.’s holdings in Edwards Lifesciences were worth $1,495,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Crewe Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 1st quarter valued at approximately $28,000. First Community Trust NA bought a new stake in shares of Edwards Lifesciences during the second quarter worth $29,000. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences during the second quarter worth $39,000. Versant Capital Management Inc lifted its stake in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the last quarter. Finally, HHM Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $55,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,250 shares of company stock worth $2,746,988 in the last ninety days. Corporate insiders own 1.27% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of recent research reports. Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Barclays lowered their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Truist Financial cut their target price on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Finally, Oppenheimer reissued an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Trading Up 0.1 %

NYSE:EW opened at $65.84 on Friday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $39.66 billion, a price-to-earnings ratio of 9.50, a PEG ratio of 3.74 and a beta of 1.12. The firm has a fifty day simple moving average of $67.75 and a two-hundred day simple moving average of $77.18.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.59 EPS. Analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.